Detection of Human Bocavirus in Respiratory, Fecal, and Blood Samples by Real-Time PCR

Sarah J. Tozer,1,2 Stephen B. Lambert,1,2 David M. Whiley,1,2 Seweryn Bialasiewicz,1,2 Michael J. Lyon,3 Michael D. Nissen,1,2,4,5 and Theo P. Sloots1,2,4,5*

1Queensland Pediatric Infectious Diseases Laboratory, Sir Albert Sakzewski Virus Research Centre, Royal Children's Hospital and Health Service District, Herston Road, Herston, Queensland, Australia
2Clinical Medical Virology Centre, University of Queensland, Queensland, Australia
3Public Health Virology Laboratory, Queensland Health Forensic and Scientific Services, Queensland, Australia
4Department of Paediatrics and Child Health, University of Queensland, Queensland, Australia
5Microbiology Division, Queensland Health Pathology Service Central, Brisbane, Queensland, Australia

Human bocavirus (HBoV) has been detected worldwide in respiratory samples. Two real-time PCR assays, targeting the non-structural protein (NP-1) and viral protein (VP-1) genes, were designed and validated to detect HBoV in patients with respiratory disease, gastroenteritis, or systemic illness. Sensitivity of the NP-1 and VP-1 assays were equal to the conventional PCR assay previously described by Allander et al. [2005: Proc Natl Acad Sci USA 102: 12891–12896] being 100%, and giving specificity of 94% and 93%, respectively. There was no cross-reaction identified with unrelated respiratory agents, or to human DNA. The limits of detection were 10 copies of genomic DNA equivalents per reaction for both assays. The assays were used to screen three different sample populations, combined nose, and throat swabs (n = 96) from children with acute respiratory disease, fecal samples (n = 375) from adults, and children with gastroenteritis and whole blood (n = 229) collected from 31 immunocompromised children taken over an 18-month period. In total 17 (18%) respiratory samples and 18 (4.8%) fecal samples were identified as having HBoV present. Of the pediatric whole blood specimens investigated, HBoV was detected in six (2.6%) samples from four patients. In summary, two real-time PCR assays targeting different genes were designed and validated for use as screening methods for the detection of HBoV. HBoV was found in three different specimen types: parent-collected combined nose–throat swabs, fecal samples collected from symptomatic individuals and whole blood from immunocompromised children.

KEY WORDS: virus; real-time PCR; blood; fecal; respiratory illness; gastroenteritis

INTRODUCTION

In 2005, a previously undetected parvovirus, human bocavirus (HBoV), was identified in respiratory samples obtained from infants in Stockholm, Sweden, using a random amplification and cloning technique [Allander et al., 2005]. Since then, HBoV has been detected in more than 17 countries in pediatric respiratory tract samples [Arden et al., 2006; Arnold et al., 2006; Bastien et al., 2006; Choi et al., 2006; Kesebir et al., 2006; Ma et al., 2006; Manning et al., 2006; Sloots et al., 2006; Smuts and Hardie, 2006; Allander et al., 2007; Fry et al., 2007; Naghipour et al., 2007; Qu et al., 2007]. These data demonstrate prevalence rates ranging from 1.5% to 19% in patients with acute respiratory illness (ARI).

HBoV is classified in the family Parvoviridae, subfamily Parvovirinae, genus Bocavirus based on...
sequence homology and is closely related to bovine parvovirus 1 and canine minute virus. Both these viruses are associated with gastroenteritis in puppies and calves [Carmichael et al., 1980; Durham et al., 1985]. HBoV has been identified in fecal samples from children with acute gastroenteritis (AGE) in Italy [Maggi et al., 2007] and Hong Kong [Lau et al., 2007]. Further, findings of HBoV in serum from patients with acute wheezing have suggested an association with systemic infection [Allander et al., 2007].

To date most studies investigating HBoV have been prevalence studies without addressing disease association. Many studies are reporting HBoV coupled to large incidences of co-infection in both respiratory and fecal samples, increasing the complexity of disease association. Not being able to apply Koch’s postulate due to the inability to culture this virus at this stage, or to be able to apply it to an animal model [Fredericks and Relman, 1996] is hampering efforts to investigate the role this virus plays in disease. Improved diagnostic assays are required to document the extent of HBoV’s presence in clinical specimens and its potential for causing disease.

To date, the methods of detecting HBoV have been conventional PCR [Allander et al., 2005; Arden et al., 2006; Bastien et al., 2006; Keserib et al., 2006; Kuper et al., 2006; Manning et al., 2006; Sloots et al., 2006] and real-time PCR [Choi et al., 2006; Manning et al., 2006; Smuts and Hardie, 2006; Allander et al., 2007; Esposito et al., 2007; Qu et al., 2007] due to the limited success of serological and viral culture techniques. Real-time PCR offers greater sensitivity, increased specificity with the addition of oligoprobes, and the added benefit of a closed detection system, reducing the likelihood of false positive results due to contamination with amplicon [Chioechan-sin et al., 2008]. Real-time platforms also offer rapid turnaround times with the ability to test for a number of gene targets with multiplexing. With PCR leading the way for the detection of viral agents [Lipson, 2002], we have developed and validated two real-time assays targeting the non-structural protein (NP-1) gene and the viral protein (VP-1) gene for the detection of HBoV in three different sample types, combined nose–throat swabs (NTS), fecal samples, and whole blood.

**MATERIALS AND METHODS**

**Samples**

Three separate banks of specimens were used in this investigation. The first set consisted of 96 community acquired NTS specimens collected from children less than 5 years of age by their parents or carers in Melbourne, Australia, between January 2003 and January 2004 with acute respiratory symptoms. The samples had previously been screened for a range of respiratory viruses [Lambert et al., 2007]. The specimens were extracted using the Corbett X-tractor Gene (Corbett Research, Australia) and tested using the HBoV PCR assays.

The second specimen bank comprised of 375 fecal samples from two different patient groups. Set A, 136 samples, were from children with AGE symptoms under the age of six presenting to the Royal Children’s Hospital Brisbane between May and September 2002. These samples were extracted using the Roche Children’s Hospital LC Instrument (Roche Diagnostics, Australia) and screened for other viral agents including adenovirus, astrovirus, norovirus, rotavirus, WU polyomavirus, KI polyomavirus, JC, and BK polyomavirus using PCR following standard conditions and published methods [Gouveia et al., 1990; Allard et al., 1992; Noel et al., 1995; Hirsch et al., 2001; Kageyama et al., 2003; Pal et al., 2006; Bialasiewicz et al., 2007]. Set B were 229 fecal samples collected by Queensland Public Health Units between June and October 2006 from patients with AGE linked to undiagnosed institutional outbreaks. These patients were children, the elderly, or staff from day-care centers, nursing homes, hostels, or hospitals throughout Queensland. The mean age was 40.3 years with the median age being 39.9 years and the age range was 1 month to 97.6 years. These samples were extracted using the Qiagen DNA Stool kit (Qiagen, Clifton Hill, Australia) and were screened using PCR for norovirus, WU polyomavirus, KI polyomavirus, JC, and BK polyomavirus using previously published methods [Hirsch et al., 2001; Kageyama et al., 2003; Pal et al., 2006; Bialasiewicz et al., 2007].

The final bank was 229 whole blood samples collected from 31 immunocompromised children with acute leukemia or post-stem cell transplant recipients. These were specimens collected at the Royal Children’s Hospital Brisbane, taken over an 18-month period beginning in July 2004. Samples were collected on consecutive weeks over an average of 9 weeks, with the longest period for consecutive sampling from one patient being 24 weeks. These children did not present with respiratory or gastrointestinal symptoms at the time of blood collection. Nucleic acids were extracted from whole blood using the Roche High Pure Viral Nucleic Acid kit (Roche Diagnostics, Castle Hill, Australia).

**Real-Time PCR Assay Design**

The primers and Taqman probes for HBoV real-time PCR were designed using Bioedit 7.0.5.3 [Hall, 1999] and Primer Express 2.0 software (Applied Biosystems Pty. Ltd., Scoresby, Australia). Briefly, Bioedit software was used to screen full length and partial genome sequences obtained from Genbank in order to identify highly conserved regions. Genbank accession numbers used were: AB248271-2, AB257721-2, AM689298, DQ000496, DQ677523, DQ457414, DQ494200-4, DQ471802-11, DQ499604, DQ267761-75, DQ513388, DQ344465-83, DQ340570, and DQ296618-35. Primer Express was then used to investigate the conserved regions and identify primer and probe targets for each gene target selected. Two assays were designed one targeting the Non-structural Protein 1 (NP-1) region and the second targeting the VP-1 (Table I).
Real-Time PCR

Both assays used the same PCR mix and cycling conditions. The primers targeting the VP-1 region were BoVP-1f and BoVP-1r and for NP-1 were BoNP-1f and BoNP-1r (Table I). The respective probes were BoVP-1f and BoVP-1r and for NP-1 were BoNP-1f and BoNP-1r (Table I). The primers targeting the VP-1 region were acquired at the end of each 60°C step. The following cycling conditions were used: initial incubation of 15 min at 95°C, followed by 50 cycles of 95°C for 15 sec, 60°C for 1 min, with fluorescence acquired at the end of each 60°C step.

Conventional PCR

The real-time assays were compared to previously published conventional PCR [Allander et al., 2005] using the same primer sets 188f GAGCTCTGTAAGAC-GACGACAGT and 542r CTCTGTGTTGACTGAATACAG. Brieﬂy, each reaction mix contained 0.4 μM of each primer, 0.5 μl of 10 mM dNTPs, 2.5 μl of 10× Qiagen PCR buffer (Qiagen), 1.0 U of Qiagen HotStart Taq (Qiagen), and 1 μl of nucleic acid extract in a final volume of 25 μl. PCR cycling was performed on an DNA Engine thermal cycler (Bio-Rad) as described above. PCR products were visualized by electrophoresis on 1.5% agarose gel with ethidium bromide staining and then puriﬁed and DNA sequenced using the ABI PRISM® BigDye sequencing kit (Applied Biosystems Pty. Ltd.).

Analytical Specificity

Analytical speciﬁcity was investigated by testing a number of organisms found as commensals or pathogens within the human respiratory tract (Table II). Human genomic DNA was also tested.

Detection Limit

Detection limits were determined using viral genomic DNA. Brieﬂy, a plasmid control was constructed using the pGEM-T-Easy vector system (Promega, Madison, USA) containing a VP-1 gene fragment. Plasmid copy number was calculated based on the molecular weight and optical density. Using the Rotogene 6000 (Corbett Research, Brisbane, Australia), 10-fold dilutions of the plasmid were tested in order to create a standard curve, which was used to quantify HBoV viral genomic DNA obtained from a clinical specimen. Dilutions of this quantiﬁed HBoV viral genomic DNA were then tested in triplicate in each assay and the limit of detection of each assay was deﬁned by the ﬁnal dilution in which all three replicates were positive for HBoV.

RESULTS

Validation of Real-Time PCR Methods

Of the 96 respiratory samples tested, 11 samples provided positive results and 79 samples provided negative results in VP-1, NP-1 real-time and conventional PCR assays. A further six samples provided discordant results. These included ﬁve samples that were positive in the conventional method. Brieﬂy, primers nestF 1 (AAGTACTATTACTTTCTTTAACACTTGGCA) and nestR 1 (CCCACACCAACCTGGAGC) were used in a ﬁrst round of PCR ampliﬁcation, following which 2 μl of ﬁrst round PCR mix was added to a second round of PCR ampliﬁcation using primers nestF 2 (GCACAGCACGCTGACGAGAAG) and nestR 2 (TTTTCCCCGATGTACACCCCC). For both nested PCR reactions, the Quantitect Probe Master Mix (Qiagen) was used as the basis for the reaction mix and 45 cycles of thermocycling were performed on a DNA Engine thermal cycler (Bio-Rad) as described above. PCR products were visualized by electrophoresis on 1.5% agarose gel with ethidium bromide staining and then puriﬁed and DNA sequenced using the ABI PRISM® BigDye sequencing kit (Applied Biosystems Pty. Ltd.).
in the VP-1 and NP-1 real-time PCR assays but were negative in conventional PCR assay (samples 1–5; Table III) and one sample that was positive in the VP-1 real-time PCR assay only (sample 6; Table III). Using the conventional assay as the reference standard, the sensitivity of both real-time NP-1 and VP-1 assays was 100%, with specificities of 94% and 93%, respectively.

All six samples providing discordant results provided high cycle threshold (Ct) values ranging from 34 to 38 (Table III), suggesting the viral loads in these samples were low and probably below the detection limit of the conventional assay. To further investigate these discordant results, these six samples were retested using a nested PCR targeting the bocavirus NP-1 gene and two of the six samples provided positive results. DNA sequencing of the nested PCR product for both specimens provided sequences with 100% homology to bocavirus NP-1 sequences on the Genbank database (accession numbers include EU984096.1, EF450739.1, DQ988934.2).

Analytical specificity was assessed by testing the assays against 25 viruses and 6 bacteria (Table II). No cross-reactions were identified with these organisms or human genomic DNA in either real-time assay.

The reliable detection limit of the VP-1 and NP-1 assays was 10 copies per reaction. The conventional PCR assay had a reliable detection limit of 100 copies per reaction.

Detection of Bocavirus in the Various Sample Types

A summary of bocavirus detection in the three sample types is provided in Table IV. Of the 17 positive respiratory samples there were four samples that showed evidence of co-infection with another virus; one had both HBoV and human metapnuemovirus (hMPV) detected and the other three contained HBoV and WU polyomavirus.

Of 136 fecal specimens collected from children, 13 (10%) were positive for HBoV by both real-time PCR assays and 8 of these were from children 1 year of age or younger. HBoV was the only pathogen detected in 62% of the positive subjects. In three specimens (23%), HBoV was co-detected with rotavirus, and in a further specimen HBoV was co-detected with rotavirus, norovirus, and adenovirus. In one case, HBoV was co-detected with adenovirus plus astrovirus. The other 239 fecal samples collected from institutional outbreak patients were also

### Table II. List of Organisms Investigated in order to Determine Specificity of the VP-1 and NP-1 Real-Time PCR Assays

| Viruses                          |     |
|----------------------------------|-----|
| Adenovirus 14 ATCC VR15          | hMPV wild-type |
| Cytomegalovirus wild-type        | Parvovirus B19 Accurun 355(Boston Biomedica, Inc., West Bridgewater, MA) |
| Coronavirus HKU1 wild-type       | Parainfluenza 1 ATCC VR 94 |
| Coronavirus NL63 wild-type       | Parainfluenza 2 ATCC VR 92 |
| Coronavirus OC43 wild-type       | Parainfluenza 3 ATCC VR 93 |
| Coronavirus 229E wild-type       | Polyomavirus JCV ATCC VR 45027 |
| Epstein bar virus wild-type      | Polyomavirus BKV ATCC VR 45024 |
| Herpes simplex virus 1 wild-type | Polyomavirus KI wild-type |
| Herpes simplex virus 2           | Polyomavirus WU wild-type |
| Influenza A ATCC VR 544          | Rhinovirus wild-type |
| Influenza B wild-type            | Respiratory syncytial virus ATCC VR 1400 |
| Measles attenuated vaccine virus  | Rubella virus wild-type |
| Ender’s line                     |     |
| Mumps vaccine virus Jeryl Lynn strain |     |
| Bacteria                        |     |
| Bartonella henselae wild-type    | Klebsiella pneumonia wild-type |
| Bordetella bronchiseptica wild-type | Legionella pneumophilla ATCC 43111 |
| Chlamydia pneumoniae wild-type   | Streptococcus pneumonia wild-type |

### Table III. The Six Specimens Providing Discordant Results Following Testing of the 96 Respiratory Samples by Both Real-Time PCR and Conventional Reference PCR Assays

| Sample no. | NP-1 RT PCR | VP-1 RT PCR | Conventional PCR | NP-1 nested PCR and sequencing |
|------------|-------------|-------------|------------------|-------------------------------|
| 1          | 37.65       | 36.17       | ND               | ND                            |
| 2          | 37.98       | 35.99       | ND               | ND                            |
| 3          | 35.22       | 34.93       | ND               | Detected<sup>a</sup>          |
| 4          | 36.66       | 36.42       | ND               | ND                            |
| 5          | 37.98       | 34.74       | ND               | Detected<sup>a</sup>          |
| 6          | ND          | 33.88       | ND               | ND                            |

A bocavirus NP-1 nested PCR and DNA sequencing was also performed for further investigation of these specimens. Cycle threshold (Ct) values are shown for real-time PCR assays.

ND, not detected.

<sup>a</sup>Bocavirus NP-1 confirmed by DNA sequencing of second round nested PCR product.

J. Med. Virol. DOI 10.1002/jmv
screened for HBoV, of these samples five (2.0%) had HBoV detected by both real-time PCR assays. Four of these had HBoV as the only identified pathogen, whereas one had a co-infection with rotavirus.

We tested 229 pediatric whole blood samples from immunocompromised children, with six (2.6%) positive specimens identified by both real-time PCR assays. One patient accounted for three of the positive samples (50%) identified. This patient had four consecutive blood samples taken over 4 weeks, with all but the week 3 specimen having HBoV detected.

DISCUSSION

In this study, we designed two real-time PCR assays for the detection of HBoV and applied it to three different sample populations to establish the prevalence of this virus. Two different gene targets, NP-1 and VP-1, were selected and applied in parallel to overcome potential false negative results due to sequence variants [Whiley et al., 2008]. When compared to the previously published conventional PCR method, these assays were found to have greater analytical sensitivity, with a detection limit of 10 copies per reaction for both assays. However, both real-time assays were statistically shown to have reduced clinical specificity (94% and 93%) compared to the conventional method. This was due to the increased number of detected samples, which were classified as false positive detections by the real-time assay on the basis that they were negative in the conventional assay. However, five out of the six additional positive samples were positive by both real-time PCR methods suggesting they were more likely true-positive samples. This is further supported by the accepted fact that real-time PCR generally has a superior limit of detection compared to conventional PCR methods. Analytical specificity was investigated and no cross-reactions were observed with unrelated viral or bacterial agents (Table II) or human genomic DNA.

The screening of 96 respiratory samples has produced a high rate of detection (18%) compared to other studies. This high rate may be attributed to the context of our study population (community based) or as a result of early collection of samples at the first signs and onset of respiratory illness. The presentation of HBoV in fecal samples from patients with AGE further suggests a possible link or role for this virus in gastroenteritis; however like respiratory specimens there was a high rate of co-detection.

This study detected HBoV in six blood samples from four patients, which confirms the previous findings of HBoV in an immunocompromised child [Schenk et al., 2007]. In our study, one of these immunocompromised subjects showed a prolonged viremia over a period of at least 4 weeks, which raises some important questions regarding reactivation or the pathogenic role of this virus in this patient population. It would be interesting to compare the results of serially collected blood specimens from asymptomatic children with and without an immununosuppressing illness.

In conclusion, we have developed and validated sensitive real-time PCR assays using two different gene targets for the identification of HBoV in different specimen types. By identifying HBoV in respiratory samples from the community, fecal samples from potential institutional outbreaks, and whole blood from asymptomatic immunocompromised children, we have confirmed that the virus may be widely distributed and raises further questions regarding its potential role in clinical illness. Clearly, HBoV needs to be further investigated as a possible viral causative agent associated with other clinical manifestations in addition to respiratory and gastrointestinal disease. The use of the highly sensitive and specific molecular assays described here will aid these investigations.

ACKNOWLEDGMENTS

All the necessary ethics approval for this study was obtained from the Institute’s (Royal Children’s Hospital) Ethics Committee. We wish to thank the staff of the Microbiology Division of the Pathology Queensland Central Laboratory.

REFERENCES

Allander T, Tammi MT, Eriksson M, Bjerkner A, Tiveljung-Lindell A, Andersson B. 2005. Cloning of a human parvovirus by molecular screening of respiratory tract samples. Proc Natl Acad Sci USA 102:12891–12896.

Allander T, Jartti T, Gupta S, Niesters HG, Lehtinen P, Osterback R, Vuorinen T, Waris M, Bjerkner A, Tiveljung-Lindell A, van den Hoogen BG, Hyypia T, Ruuskanen O. 2007. Human bocavirus and acute wheezing in children. Clin Infect Dis 44:904–910.

Allard A, Albinsson B, Wadell G. 1992. Detection of adenoviruses in stools from healthy persons and patients with diarrhea by two-step polymerase chain reaction. J Med Virol 37:149–157.

Arden KE, McErclean P, Nissen MD, Sloots TP, Mackay IM. 2006. Frequent detection of human rhinoviruses, paramyxoviruses, coronaviruses, and bocavirus during acute respiratory tract infections. J Med Virol 78:1232–1240.
Arnold JC, Singh KK, Spector SA, Sawyer MH. 2006. Human bocavirus: Prevalence and clinical spectrum at a children’s hospital. Clin Infect Dis 43:283–288.

Bastien N, Brandt K, Dust K, Ward D, Li Y. 2006. Human bocavirus infection, Canada. Emerg Infect Dis 12:848–850.

Bialasiewicz S, Whiley DM, Lambert SB, Gould A, Nissen MD, Sloots TP. 2007. Development and evaluation of real-time PCR assays for the detection of the newly identified KI and Wu polyomaviruses. J Clin Virol 40:9–14.

Carmichael LE, Jouhter JC, Pollock RV. 1980. Hemagglutination by canine coronavirus: Serologic studies and diagnostic applications. Am J Vet Res 41:784–791.

Chieochansin T, Samranasemrujakit R, Chutinimitkul S, Payungporn S, Hirantarad L, Theamoonlers A, Povorovan W. 2008. Human bocavirus (HBoV) in Thailand: Clinical manifestations in a hospitalized pediatric patient and molecular virus characterization. J Infect 56:137–142.

Choi EH, Lee HJ, Kim SJ, Eun BW, Kim NH, Lee JA, Lee JH, Song EK, Kim SH, Park JY, Sung JY. 2006. The association of newly identified respiratory viruses with lower respiratory tract infections in Korean children, 2000–2005. Clin Infect Dis 43:585–592.

Durham PJ, Lax A, Johnson RH. 1985. Pathological and virological studies of experimental parvoviral enteritis in calves. Res Vet Sci 38:209–219.

Esposito S, Lizioli A, Lastrico A, Begliatti E, Rognoni A, Tagliabue C, Menni M, Lavorgna S. 2007. Broadly reactive and highly sensitive PCR for the detection of the newly identified polyomaviruses. J Virol 81:1427–1437.

Fredericks DN, Relman DA. 1996. Sequence-based identification of microbial pathogens: A reconsideration of Koch’s postulates. Clin Microbiol Rev 9:18–33.

Fry AM, Lu X, Chittaganpitch M, Peret T, Fischer J, Dowell SF, Hirsch HH, Mohaupt M, Klimkait T. 2001. Prospective monitoring of BK virus load after discontinuing sirolimus treatment in a renal transplant patient with BK virus nephropathy. J Infect Dis 184:1494–1495, author reply 1495–1496.

Kageyama T, Kojima S, Shinohara M, Uchida K, Fujimoto S, Hoshino FB, Takeda N, Katayama K. 2005. Broadly reactive and highly sensitive assay for Norwalk-like viruses based on real-time quantitative reverse transcription-PCR. J Clin Microbiol 41:1548–1557.

Kesir D, Vazquez M, Weibel C, Shapiro ED, Ferguson D, Landry ML, Kahn JS. 2006. Human bocavirus infection in young children in the United States: Molecular epidemiological profile and clinical characteristics of a newly emerging respiratory virus. J Infect Dis 194:1276–1282.

Kupfer B, Vehreschild J, Cornely O, Kaiser R, Plum G, Viazov S, Franzen C, Tillmann RL, Simon A, Muller A, Schildgen O. 2006. Severe pneumonia and human bocavirus in adult. Emerg Infect Dis 12:1614–1616.

Lambert SB, Allen KM, Druce JD, Birch CJ, Mackay IM, Carlin JB, Carapetis-JR, Sloots TP, Nissen MD, Nolan TM. 2007. Community epidemiology of human metapneumovirus, human coronavirus NL63, and other respiratory viruses in healthy preschool-aged children using parent-collected specimens. Pediatrics 120:e929–e937.

Lau SK, Yip CC, Que TL, Lee RA, Au-Yeung RK, Zhou B, So LY, Lau YL, Chan KH, Woo PC, Yuen KY. 2007. Clinical and molecular epidemiology of human bocavirus in respiratory and fecal samples from children in Hong Kong. J Infect Dis 196:986–993.

Maggi F, Andreoli E, Pifferi M, Meschi S, Rocchi J, Bendinelli M. 2007. Human bocavirus in Italian patients with respiratory diseases. J Clin Virol 38:321–325.

Noel JS, Lee TW, Kurtz JB, Glass RI, Monroe SS. 1995. Typing of human astroviruses from clinical isolates by enzyme immunoassay and nucleotide sequencing. J Clin Microbiol 33:79–801.

Pal A, Sirota L, Maudru T, Peden K, Lewis AM Jr. 2006. Real-time, quantitative PCR assays for the detection of virus-specific DNA in samples with mixed populations of polyomaviruses. J Virol Methods 135:32–42.

Qu JW, Duan ZJ, Qi ZY, Xie ZP, Gao HC, Liu WP, Huang CP, Peng FW, Zheng LS, Hou YD. 2007. Human bocavirus infection, People’s Republic of China. Emerg Infect Dis 13:165–168.

Schenk T, Strahm B, Konty U, Hufnagel M, Neumann-Haefelin D, Falcone V. 2007. Disseminated bocavirus infection after stem cell transplant. Emerg Infect Dis 13:1425–1427.

Sloffs TP, McErlean P, Speicher DJ, Arden KE, Nissen MD, Mackay IM. 2006. Evidence of human coronavirus HKU1 and human bocavirus in Australian children. J Clin Virol 35:99–102.

Smuts H, Hardie D. 2006. Human bocavirus in hospitalized children, South Africa. Emerg Infect Dis 12:1457–1458.

Whiley DM, Lambert SB, Bialasiewicz S, Goire N, Nissen MD, Sloots TP. 2008. False-negative results in nucleic acid amplification tests—Do we need to routinely use two genetic targets in all assays to overcome problems caused by sequence variation? Clit Rev Microbiol 34:71–76.